塔克达的登革热疫苗Qdenga在一次大型试验中显示出强大而持久的保护作用, 已在11个国家使用, 但在美国仍未提供. Takeda’s dengue vaccine Qdenga showed strong, lasting protection in a major trial and is used in 11 countries, but remains unavailable in the U.S.

Takeda的登革热疫苗Qdenga(Qdenga)在一次大型试验中表现出了长达4.5年的持续保护,其中61.2%对经证实的登革热有效,84.1%对住院有效,在加速器后上升到90.6%。 Takeda’s dengue vaccine Qdenga showed sustained protection for up to 4.5 years in a large trial, with 61.2% efficacy against confirmed dengue and 84.1% against hospitalization, rising to 90.6% after a booster. 该疫苗对拉丁美洲20 000多名儿童进行了研究,针对所有四种登革热血清型,没有出现新的安全问题。 The vaccine, studied in over 20,000 children across Latin America, worked against all four dengue serotypes with no new safety issues. 它在41个国家获得批准,在11个国家分发,交付剂量1 860万剂。 It has been approved in 41 countries and distributed in 11, with 18.6 million doses delivered. 巴西使用Qdenga与病例减少和住院有关。 Brazil’s use of Qdenga correlated with reduced cases and hospitalizations. 在全球登革热病例激增的同时,到2024年,登革热病例将超过1400万例. 在美国,Qdenga仍然无法使用,因为Takeda在2023年撤回了FDA的申请. Amid a global dengue surge—over 14 million cases in 2024—Qdenga remains unavailable in the U.S., where Takeda withdrew its FDA application in 2023.